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Background and objective: T cell-mediated immunity plays an important role in enhancing antitumor response.
This study aimed to investigate the changes in the T-lymphocyte subpopulation and to characterize the differential
expression pattern of corresponding regulatory genes in peripheral blood mononuclear cells (PBMCs) from diffuse
large B cell lymphoma (DLBCL) patients before and after chemotherapy.
Methods: A total of 56 DLBCL patients were recruited for analysis of T-cell subset distribution in the peripheral
blood using flow cytometry; serum interferon (IFN)-γ and interleukin (IL)-4 levels using enzyme-linked
immunosorbent assays; and early growth response protein 1 (EGR-1), T-bet, GATA-binding protein 3 (GATA-3), and
transforming growth factor (TGF)-β mRNA levels using quantitative reverse-transcription polymerase chain reaction.
Twenty-six healthy subjects served as controls.
Results: The percentage of CD3+CD4+T lymphocytes in peripheral blood from DLBCL patients was significantly
decreased, whereas the percentages of CD3+CD8+T and CD4+CD25+T cells were significantly increased compared
to those in controls (p < 0.05). Serum levels of IFN-γ and IL-4 were also significantly lower in DLBCL patients than
those in controls (p < 0.05), and the levels of EGR-1, T-bet, and GATA-3 mRNA in PBMCs were lower (2.69 ± 1.48,
9.43 ± 2.14, and 20.83 ± 9.05 fold, respectively) in DLBCL patients than those in controls. Furthermore, there was a
positive association between the levels of EGR-1 and T-bet mRNA (p = 0.001). However, the level of TGF-β mRNA
was significantly increased in DLBCL patients, which was inversely associated with the T-bet mRNA level (p = 0.008),
but positively associated with the percentage of T regulatory cells in PBMCs (p = 0.011). After three cycles of
chemotherapy, the distribution of T-lymphocyte subsets in DLBCL patients were changed, and the levels of EGR-1,
T-bet, and GATA-3 mRNA were significantly increased (p < 0.05) compared to those before chemotherapy.
Conclusions: These results demonstrate the changes in T-lymphocyte subpopulations and the altered expression
34 pattern of the corresponding regulatory genes in PBMCs from DLBCL patients after chemotherapy, which are
associated with the response of patients to treatment. The preferential expression of the T-bet gene after
chemotherapy was closely correlated with the increased expression of the EGR-1 gene and decreased expression of
the TGF-β gene.
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Diffuse large B cell lymphoma (DLBCL) is the most com-
mon type of non-Hodgkin lymphoma in adults and is
an aggressive malignancy that can arise in any part of
the body [1]. At present, the standard treatment for DLBCL
is chemotherapy and combination treatment with an
antibody-targeted therapy. Most patients do experience
good survival with a curable rate of more than 70% [2]. The
precise mechanism of the development of DLBCL is not
yet clear. However, it is accepted that the reason is a syner-
gistic effect of extrinsic and intrinsic factors, and the switch
in the immune state is an explanation for the development
of DLBCL that has received great attention [3-5]. In the
normal physiological state, B lymphocytes regulate the
humoral immunity, a vital part of the adaptive immune sys-
tem in the human body. Upon pathogen invasion, specific
T lymphocytes will proliferate or differentiate to effector or
memory T cells. Helper T cells (i.e., CD4+T cells) then acti-
vate specific B cells to produce antibodies for the inhibition
or elimination of pathogens. Thus, CD4+T cells play a
central role in immune protection by promoting B cell
secretion of antibodies. Unfortunately, the function of B-
lymphocytes is seriously deficient in DLBCL patients, which
leads to abnormal humoral immune response [6-8]; simi-
larly, the cellular immunity is extremely impaired [5,9-13].
A previous study identified two subsets of CD4+T lym-
phocytes based on cytokine production and function
[14]. To date, it was found that naive CD4+ T helper
cell (Th) precursors can differentiate into functionally
distinct T cell lineages at least including Th1, Th2, Th17,
and T regulatory (Treg) cells upon activation [15]. Among
the critical signals that direct the induced patterns of gene
expression in maturing helper T cell subsets are cytokine-
induced specific transcription factors. IL-12 drives Th1
cell differentiation through the activation of the tran-
scription factors STAT4 and T-bet [16,17], and Th1
cells mainly secrete several cytokines, such as IL-2 and
IFN-γ to meditate cellular immunity. IL-4 induces Th2
cell differentiation through the actions of STAT6 and
GATA-3 [18], and Th2 cells can produce the immuno-
logical factors (such as IL-4 and IL-10) to stimulate
B-cell proliferation and antibody production. Whereas
Th17 cells differ from Th1 and Th2 cells, whose devel-
opment is prompted by a combination of IL-6 plus
TGF-β and requires expression of STAT3 and the RAR-
related orphan receptor gamma t (RORγt) [19], and
mainly meditate inflammatory reactions, autoimmune
diseases, and transplantation rejections, and are closely
related to Treg cells. Treg cells negatively regulate immune
function in the anti-inflammatory reaction and mainten-
ance of immune tolerance by secreting cytokines (e.g., IL-
10 and TGF-β). TGF-β is a pleiotropic cytokine, involved
in many different critical processes, such as embryonal de-
velopment, cellular maturation and differentiation, woundhealing, and immune regulation. Paradoxically, in cancer,
TGF-β has been demonstrated to be a potent inhibitor of
cell proliferation and acts as a tumor suppressor at the be-
ginning of tumorogenesis. However, once the cells become
resistant to TGF-β, it mainly supports tumor growth and
metastasis by promoting immune evasion and angiogenesis
[20]. The number and function of these cell types are
essential to maintain the balance of the immune system
in vivo, especially, in the cross regulation and interrestraint
between Th1 and Th2 cells, which can be indirectly
detected by analysis of the characteristic cytokines [15].
For example, IFN-γ and IL-4 are representative and im-
portant stimulating factors that induce differentiation of
Th1 and Th2 cells, respectively, and consequently indicate
the dynamic equilibrium between Th1 and Th2 cells.
Furthermore, T-bet and GATA-3 are important trans-
cription factors in regulating Thl/Th2 cell differentiation.
T-bet over-expression induces differentiation into the Th1
lineage, whereas loss of T-bet expression induces the cells’
default commitment to Th2 and Th17 lineages, resulting
in impaired Th1 immunity. In contrast, knockdown of
GATA-3 expression prevents the cells from differentiating
into the Th2 lineage and over-expression in Th1 cells
switches their polarity to a Th2 phenotype [21,22]. EGR-1
is a multifunctional nuclear transcriptional factor that
belongs to a family of early response genes. It induced by
pre-TCR signaling has been found to be important in
regulation of the early stages of T-lymphocyte develop-
ment, especially for the CD4−CD8− double negative (DP)
to the CD4+CD8+ double positive (DP) transition [23]; in
addition, recent studies have also described EGR-1 as
a tumor repressor that directly or indirectly upregulates
multiple tumor suppressors, including PTEN, TP53,
fibronectin, BCL-2, and TGF-β1, to inhibit cell growth,
proliferation, and metastasis, as well as induce apoptosis
[24,25]. Nevertheless, during B-lymphocyte tumorigenesis,
the distribution of these T cells and the expression of
corresponding regulatory genes could be altered [26],
and detection of such alterations and gene expression
patterns could be useful in monitoring DLBCL progres-
sion and treatment responses.
In our previous studies, we showed that antitumor T-
cell clones exist in peripheral blood of DLBCL patients,
but they do not possess effective antitumor activity
[11,12], which may be due to T-cell anergy, an imbal-
ance of T-cell subsets, or suppression of the immune
system. However, little is known about the distribution
of T-lymphocyte subpopulations and the expression pat-
terns of different genes in DLBCL patients before and after
chemotherapy. In the present study, we aimed to investi-
gate the changes in T-lymphocyte subpopulations and
modulation of corresponding cytokines and transcription
factors (such as TGF-β, EGR-1, GATA-3, and T-bet) in
PBMCs from DLBCL patients after chemotherapy.
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Redistribution of lymphocyte subsets in PBMCs from
DLBCL patients
The percentage of CD3+T lymphocytes did not differ
between healthy controls (72.90 ± 5.83%) and DLBCL
patients at baseline (72.09 ± 3.16%; p > 0.05) or after
three cycles of chemotherapy (71.24 ± 6.2%; p > 0.05).
However, the percentage of CD3+CD4+T cells was
significantly decreased (p = 0.023), and the percent-
ages of CD3+CD8+ and CD4+CD25+T lymphocytes
(p = 0.012 and p = 0.002, respectively) were all signifi-
cantly increased in DLBCL patients at baseline com-
pared to the healthy controls, resulting in a severe
inversion of the CD4/CD8 ratio (Table 1). Moreover,
after three cycles of chemotherapy, the percentage of
CD3+CD8+T lymphocytes was significantly decreased
(p = 0.015), whereas the percentages of CD3+CD4+
and CD4+CD25+T lymphocytes were increased (p = 0.095
and p = 0.009, respectively) compared to those at baseline
(Table 1). The percentages of CD3+CD4+ T lymphocyte
at baseline or after three cycles of chemotherapy in
stage III and IV disease were lower than those in stage I
and II disease, and the percentage of CD3+CD8+ and
CD4+CD25+T lymphocytes at baseline or after three
cycles of chemotherapy in stage III and IV disease were
higher than those in stage I and II disease, yet there
were no statistical significance between two groups
(every p > 0.05).Identification of PCR amplification fragments
The amplification efficiency for EGR-1, T-bet, GATA-3,
and TGF-β mRNA was consistent with that of the refer-
ence gene GAPDH. All of these transcripts were de-
tected in all of the PBMC samples from the healthy
controls and DLBCL patients. The peaks of the melting
curves of PCR products for GAPDH mRNA occurred at
84°C. The peaks of the melting curves for T-bet, GATA-
3, EGR-1, and TGF-β mRNA were at 86°C, 79°C, 85°C,
and 89°C, respectively (Figure 1). All PCR products
were confirmed using 2% agarose gel electrophoresis
(Figure 2), and the results showed that the amplified
fragments of T-bet, GATA-3, EGR-1, TGF-β, and GAPDH
were 159, 204, 160, 203, and 207 bp, respectively, and were
consistent with the expected sizes.Table 1 Distribution of T-lymphocyte subsets (mean ± SE) in D
chemotherapy
Group N CD3+ T
cells (%)
DLBCL patients at baseline 56 72.09 ± 3.16
DLBCL after three cycles of chemotherapy 56 71.24 ± 6.2
Healthy controls 26 72.90 ± 5.83Altered levels of EGR-1, T-bet, GATA-3, and TGF-β mRNA
in PBMCs from DLBCL patients at baseline
The levels of EGR-1, T-bet, and GATA-3 mRNA in
PBMCs from DLBCL patients at baseline were signifi-
cantly lower than those from the healthy controls (p <
0.05; Figure 3). Specifically, the EGR-1 mRNA level was
decreased by 2.69-fold (±1.48), the T-bet mRNA level was
decreased by 9.43-fold (±2.14), and the GATA-3 mRNA
level was decreased by 20.83-fold (±9.05). Furthermore,
there was a positive association between the levels of
EGR-1 and T-bet mRNA in PBMCs from patients before
chemotherapy (r = 0.84, p = 0.001; Figure 4). However, the
level of TGF-β mRNA was higher by 2.01-fold (±0.51) in
baseline PBMCs from DLBCL patients than that in the
healthy controls. Furthermore, the levels of T-bet and
GATA-3 mRNA in stage III and IV disease were lower
than those in stage I and II disease, although there was
no statistical significance (p > 0.05). The levels of EGR-
1mRNA in stage III and IV disease were significantly
lower than those in stage I and II disease (Table 2). In con-
trast, the level of TGF-β mRNA was higher in stage III
and IV patients than those in stage I and II patients, yet
there was no significant difference between two groups
(Table 2). Moreover, an inverse association occurred be-
tween the levels of T-bet and TGF-β mRNA (r = −0.69,
p = 0.008; Figure 5). There was no statistical association
between the levels of GATA-3 and TGF-β mRNA. In
addition, the level of TGF-β mRNA was positively associ-
ated with the percentage of Treg lymphocytes in periph-
eral blood (r = 0.39, p = 0.011; Figure 6).
Differential expression of serum IFN-γ and IL-4 levels in
DLBCL patients at baseline
Compared to healthy controls, serum levels of IFN-γ
(19.7 ± 10.5 pg/mL) and IL-4 (1.2 ± 1.4 pg/mL) in DLBCL
patients were significantly lower at baseline (p = 0.000 and
p = 0.001; Figure 7). Moreover, there was a positive associ-
ation between serum IFN-γ level and T-bet mRNA level
in PBMCs (r = 0.64, p = 0.018; Figure 8). The same was
true between serum IL-4 level and GATA3 mRNA level in
PBMCs (r = 0.71, p = 0.005; Figure 8). Although the serum
levels of IFN-γ and IL-4 at baseline in stage III and IV pa-
tients were lower than those in stage I and II patients,
there were no statistical significance between two groups









32.31 ± 3.65 37.53 ± 6.46 0.85 ± 0.49 5.48 ± 4.96
34.09 ± 4.63 32.51 ± 5.25 1.06 ± 0.87 8.32 ± 3.54
41.78 ± 4.23 28.51 ± 2.14 1.47 ± 0.27 3.68 ± 1.03
Figure 1 Electrophoresis of PCR-amplified fragments. The fragment lengths of amplification products were 159, 204, 160, 203, and 207 bp. 1,
100-bp marker; 2 and 3: T-bet; 4 and 5: GATA-3; 6 and 7: EGR-1; 8 and 9: TGF-β; 10 and 11: GAPDH.
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in PBMCs from DLBCL patients after chemotherapy
After three cycles of chemotherapy, 36 DLBCL patients
experienced complete remission (CR), whereas 20 DLBCL
patients achieved partial remission (PR). The levels of
EGR-1, T-bet, and GATA-3 mRNA were significantly
higher than those before chemotherapy by 6.17-fold
(±1.43), 4.84-fold (±0.95), and 3.61-fold (±1.06), respect-
ively (p < 0.05; Table 3). EGR-1 mRNA level was the most
significantly increased, reached 2.5 (±0.65) folds compared
to that of healthy controls. The increase in the T-bet
mRNA level was apparently higher than that in the
GATA-3 mRNA level (p = 0.002). However, the levels of
the two transcription factors were still lower by 1.98-fold
(±1.10) and 5.71-fold (±1.62), respectively, than those in
healthy controls. The levels of GATA-3, T-bet, and EGR-1
mRNA were significantly higher in CR patients than those
in PR patients (p = 0.025, p = 0.005, and p = 0.002, respect-
ively; Figure 9). However, the level of TGF-β mRNA wasFigure 2 qPCR detection of the peaks of melting curves for each tran
GATA-3, EGR-1, TGF-β, and GAPDH reference gene were at 84°C, 86°C, 79°Cstill higher than that in healthy controls by 1.24-fold
(±0.57), although the chemotherapy reduced the TGF-β
mRNA level by 1.6-fold (±1.04). In addition, the TGF-β
mRNA level was lower in CR patients than in PR patients
(p = 0.013; Figure 8).
Discussion
Accumulating research findings led to the conclusion/
suggestion that there are multiple antitumor T-cell
clones in the peripheral blood of DLBCL patients, but
these T lymphocytes fail to retain effective antitumor
properties [11,12]. The reason remains to be determined,
but it may be due to the T-cell immune anergy and
tumor immune escape resulting from imbalance of T-
lymphocyte subsets. Indeed, our previous study showed
that imbalance T-lymphocyte subsets occurs in PBMCs
of DLBCL patients during different chemotherapy
stages, and these T-lymphocyte subsets gradually return
to normal by 3 months after chemotherapy [27]. CD4+Tscript. The peaks of the melting curves of PCR products for T-bet,
, 85°C, and 89°C, respectively.
Figure 3 Relative expression levels of EGR-1, T-bet, GATA-3, and TGF-β mRNA in DLBCL patients before and after three cycles of
chemotherapy. Gene expression was detected using qRT-PCR.
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response. Under normal circumstances, immature CD4+ T
(Th0) cells differentiate into certain mature subtype
for specific immune response by antigen and cytokine
stimulation. Both IFN-γ and IL-4, representative cyto-
kines secreted by Th1 and Th2 cells, are main factors
that stimulate and induce Th0 cell differentiation into
Th1/Th2 cells. In the current study, we found that the
percentage of CD4+ T cells was strikingly decreased in
PBMCs from DLBCL patients, whereas the percentage
of Treg cells was unusually high, resulting in few cyto-
kines secreted by Th1 and Th2 cells, the imbalance of
which could always be assessed by the expression levels
of these two cytokines [28].
Furthermore, both T-bet and GATA-3 are key transcrip-
tion factors in regulating Th1/Th2 cell differentiation;Figure 4 Association of the relative expression levels of EGR-1 and T-
an obvious positive association between the expression levels of EGR-1 andthus, their expression directly affects the dynamic balance
of the Th1/Th2 subpopulations. A previous study demon-
strated that decreased T-bet expression and increased
GATA-3 expression occurred in PBMCs of patients with
different solid tumors [29], whereas increased T-bet ex-
pression and decreased GATA-3 expression were found in
aplastic anemia patients [30]. However, to date, their
expression levels are unknown in PBMCs from DLBCL
patients. Our current data revealed that the levels of
these two transcription factors were significantly lower in
DLBCL patients than those in healthy controls, suggesting
that there were few Th1 and Th2 cells in the peripheral
blood of DLBCL patients. Their expression levels were
even lower in DLBCL patients with stage III or IV disease
than in those with stage I or II disease, which also suggests
that patients with disseminated lesions have furtherbet genes in PBMCs from DLBCL patients at baseline. There was
T-bet mRNA. Gene expression was detected using qRT-PCR.
Table 2 Differential gene expression between DLBCL patients with different disease stages at baseline
EGR-1 T-bet GATA-3 TGF-β
ΔΔCt1 2-ΔΔCt1 ΔΔCt1 2-ΔΔCt1 ΔΔCt1 2-ΔΔCt1 ΔΔCt2 2-ΔΔCt2
Stage I-II −0.120 ± 0.67 1.09 ± 0.23 −2.496 ± 0.568 5.65 ± 1.05 −3.742 ± 0.714 13.33 ± 2.65 0.723 ± 0.793 0.605 ± 0.51
Stage III-IV −2.952 ± 0.851 7.69 ± 2.10 −4.099 ± 1.272 17.24 ± 4.23 −5.143 ± 1.632 35.71 ± 12.41 1.337 ± 0.931 0.395 ± 0.46
P 0.008* 0.068 0.144 0.092
Note: ΔΔCt1 = ΔCttarget gene in control-ΔCttarget gene in patients,2
-ΔΔCt1 indicates the fold decrease in the expression of target genes in patients compared to controls.
ΔΔCt2 = ΔCt TGF-β in patient-ΔCt TGF-β in control, 2
-ΔΔCt2 indicates the fold increase in TGF-β expression in patients compared to controls. *indicates that there is
significant difference between two groups.
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capacity compared to patients with localized lesions.
After three cycles of chemotherapy, the levels of T-bet
and GATA-3 mRNA had increased significantly. How-
ever, it remains to be further investigated whether the
increased levels of T-bet and GATA-3 mRNA contrib-
ute to the restoration of Th1 cell immune function.
Effective immune responses against different antigens
are dependent on T-cell differentiation. T-bet, one of the
specific transcription factors, is vital in all three important
differentiation pathways of Th1 cells, i.e., TCR/EGR1,
INF-γ/STAT-1, and IL-12/STAT-4 signaling pathways. A
low level of INF-γ is needed for the initial activation of
T-bet, which intensely stimulates the Tbx21 gene and
promotes expression of T-bet through the INF-γ/STAT-
1 signaling pathway [31]. Thus, the balance of T-bet and
GATA-3 gene expression should be appropriately mod-
ulated during treatment, especially in elderly patients
with disseminated lesions. IFN-γ intervention not only
directly inhibits tumor growth but also improves in vivo
T-bet expression after chemotherapy to promote the
early reconstruction of Th1 cells and enhance antitumor
immune responses. Most importantly, the TCR/EGR-1
pathway strikingly induces T-bet expression compared
to the other two signaling pathways [32]. Notably, over-Figure 5 Association of the relative expression levels of TGF-β and T-
an obvious negative association between the expression levels of TGF-β anexpression of EGR-1 through binding of EGR-1 to T-bet
promoter transactivates, in concert with TCR signaling,
and synergistically induces T-bet expression [33]. In
the current study, we found that the level of EGR-1was
reduced in DLBCL patients and was even lower in pa-
tients with disseminated lesions than that in patients
with localized lesions. Interestingly, the level of EGR-1
mRNA was significantly increased by more than 2-fold
in DLBCL patients after three cycles of chemotherapy.
Meanwhile, T-bet expression was also apparently in-
creased, and the increased level of T-bet mRNA was
significantly higher than that of GATA-3 mRNA, sug-
gesting that EGR-1 was positively associated with T-bet
expression.
Indeed, Th1 plays an important role in enhancing the
response in cell-mediated immunity. In contrast, the
effects of Th2 cells mediate humoral immunity. Thus,
these two types of cells are essential in maintaining the
balance of the immune system. In the current study, we
tried to understand the levels and balance of Th1/Th2
cells in PBMCs from DLBCL patients by analyzing corre-
sponding transcription factors and cytokines in DLBCL
patients. Our data showed that the levels of Th1 and Th2
cells were significantly lower in DLBCL patients than
that in normal individuals, which will inevitably causebet genes in PBMCs from DLBCL patients at baseline. There was
d T-bet mRNA. Gene expression was detected using qRT-PCR.
Figure 6 Association of the relative expression levels of TGF-β genes and the percentage of Treg cells in peripheral blood from DLBCL
patients at baseline. There was an obvious positive association between the expression levels of TGF-β and the percentage of Treg cells. Gene
expression was detected using qRT-PCR, and Treg cells were sorted by flow cytometry.
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in DLBCL patients. In addition, tolerance induction in
T cells takes place in most tumors and is thought to
account for tumor evasion from immune eradication.
Increased expression of cytokine TGF-β from tumor
cells and T cells is associated with the occurrence,
development, and prognosis of tumors by promoting
tumor progression and inhibiting the immune response
and surveillance system in vivo [34-37]. Our current study
demonstrated that over-expression of TGF-β mRNA in
PBMCs from patients at baseline was positively associated
with a higher percentage of Treg cells, the increase of
which was related to the patient’s immune tolerance and
tumor immune escape. The level of TGF-β mRNA was
reduced significantly after chemotherapy, but was still
higher than that in healthy controls. TGF-β inhibition of
the immune system is activated mainly through the ERK-2Figure 7 Serum levels of IFN-γ and IL-4 proteins in DLBCL patients at
IFN-γ and IL-4 were significantly lower in DLBCL patients at baseline. Serumpathway to affect expression of multiple transcription fac-
tors (e.g., T-bet and GATA-3), which seriously hampers
Th1 and Th2 cell differentiation and promotes the gener-
ation of Foxp3(+) Treg cells [38,39], consistently with our
current findings.
In summary, the current results demonstrate, for the
first time, the changes of distribution of Th1/Th2 cells
and the altered expression pattern of the corresponding
regulatory genes in PBMCs from DLBCL patients after
chemotherapy, which are associated with the response
of patients to treatment. The preferential expression of
the T-bet gene after chemotherapy was closely corre-
lated with the increased expression of the EGR1 gene
and decreased expression of the TGF-β gene. Thus, the
data from the current study demonstrate that immune
regulation therapy may be useful as adjuvant treatment
in DLBCL patients in the future.baseline. Compared to those in the healthy controls, serum levels of
levels of IL-4 and IFN-γ proteins were detected by ELISA.
Figure 8 Association of serum IFN-γ/IL-4 levels at baseline and the relative expression levels of T-bet/GATA-3 genes. There was a positive
association between serum IFN-γ level and T-bet mRNA level, yet between serum IL-4 level and GATA3 mRNA level in PBMCs. Serum IL-4 and IFN-γ
levels were detected by ELISA, and gene expression was detected using qRT-PCR.
Yin et al. Cancer Cell International  (2014) 14:85 Page 8 of 11Patients and methods
Study population
A total of 56 patients (26 females and 30 males, median
age 48 years, range from 24 to 72 years) were recruited
from the Affiliated Cancer Hospital of Zhengzhou
University between March 2009 and April 2013. These
patients were newly diagnosed with DLBCL based on
routinely accepted clinical and laboratory criteria with
histological/cytological confirmation. According to the
Ann Arbor standard staging criteria, all the patients
were staged by color Doppler ultrasound, computed
tomography, bone marrow biopsy, and serum lactate
dehydrogenase levels. None of these 56 patients showed
any bone marrow involvement. Clinically, 27 patients were
at stage I to II, and 29 were at stage III to IV. Nineteen
patients were older than 60 years old (i.e., 9 at stage II
and 10 at stage III). All patients received CHOP (25
patients), CHOP-B (12 patients), or R-CHOP (19 patients)
chemotherapy regimens. CHOP chemotherapy was
administered as follows: one course of chemotherapy
consisting of an intravenous infusion of 750 mg/m2
cyclophosphamide, 50 mg/m2 adriamycin, 2 mg vin-
cristine, and an oral administration of 100 mg prednis-
one on days 1 to 5, which was repeated every 3 weeks. For
the R-CHOP regimen, 375 mg/m2 rituximab was infused
over 4 to 6 hours on day 1 before CHOP chemotherapy
was started. For the CHOP-B regimen, intravenous bleo-
mycin (15 mg/m2) was added on the basis of a standardTable 3 Differential gene expression in DLBCL patients before
EGR-1 T-bet
ΔΔCt1 2-ΔΔCt ΔΔCt1
Before chemotherapy −1.427 ± 0.565 2.67 ± 1.48 −3.236 ± 1.
After three cycles of chemotherapy 1.117 ± 0.644 0.44 ± 0.23 −0.987 ± 0.
p 0.001* 0.002*
Note: ΔΔCt1 = ΔCt target gene in control-ΔCt target gene in patients, 2
-ΔΔCt1 indicates the fold
ΔΔCt2 = ΔCt TGF-β in patient-ΔCt TGF-β in control, 2
-ΔΔCt2 indicates the fold increase in TG
significant difference between two groups.CHOP scheme. Treatment efficacy was evaluated after
three cycles of chemotherapy. This study was approved by
our hospital review board, and each patient signed a con-
sent form for participation in this study.
Collection and analysis of blood samples
Peripheral blood samples were collected from 56 DLBCL
patients and 26 healthy volunteers, and blood was with-
drawn twice for the patients (at baseline and before the
fourth chemotherapy cycle). The blood samples were im-
mediately processed, and 1 mL serum from each subject
was frozen and stored at −20°C until use. The PBMCs
were obtained using the Ficoll-Hypaque gradient centrifu-
gation method within 1 hour after blood sample collec-
tion. Samples of 5-10 × 105 PBMCs from each patient at
baseline and before the fourth chemotherapy cycle were
used for flow cytometric detection of T-lymphocyte sub-
sets, and the remaining cells were stored at −70°C for ana-
lysis of cytokines and transcription factors.
Flow cytometric (FCM) detection of T-lymphocyte subsets
Flow cytometry was used to assess the distributions of
CD3+, CD3+CD4+, CD3+CD8+, and CD4+CD25+CD127−T
cells in PBMCs from healthy volunteers and patients at
baseline and before the fourth cycle of chemotherapy.
Monoclonal anti-CD3-PECY5, CD4-FITC, CD8-PE, and
CD25-PE antibodies (BD Biosciences, San Diego, CA,
USA) were used for the FCM detections according toand after chemotherapy
GATA-3 TGF-β
2-ΔΔCt ΔΔCt1 2-ΔΔCt ΔΔCt2 2-ΔΔCt
667 9.43 ± 2.14 −4.388 ± 0.839 20.83 ± 9.05 1.001 ± 0.943 2.01 ± 0.51
606 1.98 ± 1.10 −2.517 ± 0.796 5.71 ± 1.62 0.314 ± 0.268 1.24 ± 0.57
0.028* 0.095
decrease in the expression of target genes in patients compared to controls.
F-β expression in patients compared to controls. *indicates that there is
Figure 9 Relative expression levels of GATA-3, T-bet, EGR-1, and
TGF-β genes in CR patients and PR patients after three cycles
of chemotherapy.












Yin et al. Cancer Cell International  (2014) 14:85 Page 9 of 11the manufacturer’s instructions. The EP-ICS2XL flow
cytometer (Beckman Coulter, Brea, CA, USA) was used
for acquisition and analysis of FCM data.
ELISA detection of serum IL-4 and IFN-γ levels
Serum levels of IL-4 and IFN-γ proteins from DLBCL
patients at baseline were assessed using corresponding
enzyme-linked immunosorbent assay (ELISA) kits (Takara,
Dalian, China) according to the manufacturer’s protocols.
Briefly, 100 μL of serum samples was added to each well of
microwell plates previously coated with a polyclonal anti-IL-
4 or IFN-γ antibody, and the plates were incubated for 2 h
at room temperature. After a wash with phosphate-buffered
saline (PBS), a polyclonal biotin-conjugated IL-4 or IFN-γ
antibody was added to each well, and the plates were further
incubated for 1 h at room temperature. After washing,
streptavidin-horseradish peroxidase (HRP) was added to
each well and incubated for 1 h, and then the unbound
streptavidin-HRP was washed away. Next, the color reagent
for HRP was added to the wells, and the absorbance was
measured at 450 nm using an Elx808IU Ultra Microplate
Reader (Bio-Tek, Winooski, VT, USA). A standard curve
was constructed using the IL-4 or IFN-γ protein standards
provided in the kits. Each sample was analyzed in triplicate.
RNA isolation and qRT-PCR
Total cellular RNA was isolated from 1-5 × 106 PBMCs
using a Trizol reagent (Invitrogen, Carlsbad, CA, USA)
and then 2 μg RNA was reversely transcribed into the
first single-strand cDNA using random hexamer primers
and the Superscript II reverse transcriptase Kit (Invitro-
gen, USA) according to the manufacturer’s instructions.
The RNA quality was analyzed in 0.8% agarose gel
stained with ethidium bromide. The cDNA quality was
confirmed by RT-PCR for glyceraldehyde-3-phosphate
(GAPDH) reference gene amplification.
For the detection of EGR-1, T-bet, GATA-3, TGF-β,
and GAPDH reference gene mRNA levels by SYBRGreen I real-time PCR (Ex Taq II-DRR820A, Takara),
the primers (Table 4) were synthesized by Shanghai
SANGON Biological Engineering Technology Services
Co., Ltd. (Shanghai, China). PCR amplification was per-
formed using an ABI 7300 (Applied Biosystems, Foster
City, CA, USA) in a 25 μL total volume containing
50 ng/ μL cDNA, 10 μmol/ L primer pairs, 10 μL of 2 ×
Real Master Mix (Ex Taq II-DRR820A, Takara), and
0.4 μL ROX (Ex Taq II-DRR820A, Takara) with an initial
denaturation at 95°C for 30 s and then 40 cycles of 95°C
for 15 s and 61°C for 31 s. Additionally, a specific ampli-
fication of the PCR products was analyzed by melting
curve analysis and agarose gel electrophoresis. On the
basis of the consistent amplification efficiency for each
of target genes and GAPDH reference gene, the relative
amount of the target genes was normalized to that
of GAPDH mRNA in two independent assays using the
2-△Ct × 100% and 2-△△Ct methods [40-42].Statistical analysis
All statistical analyses were performed using the Statistical
Package for Social Sciences software (SPSS 18.0, Chicago,
IL, USA), and the data are presented as mean ± standard
error (SE). Differences in mRNA levels between the
two groups were analyzed using Student’s t test. The
Spearman’s rank correlation analysis was performed to
detect differences in the mRNA expression of EGR-1,
T-bet, GATA-3, and TGF-β in different samples. P < 0.05
was considered statistically significant.
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